

organized by:



in collaboration with:



under the auspices of:



IMMUNOTHERAPY bridge 2021



Virtual meeting
December 1st - 2nd

2021

GENERAL INFORMATION



CME PROVIDER AND ORGANIZING AGENCY:

3P Solution Srl

Corso Magenta 81, 20123 Milan

Phone +39 02 36631574

www.3psolution.it

info@3psolution.it

info@melanomabridge.org

OFFICIAL LANGUAGE:

The official language is English

REGISTRATION:

This year the registration will be **free of charge** for all HCPs, but only registered attendees will be admitted to the meeting.

To register:

- go to: www.melanomabridge.org/registration-key-dates.php and click on REGISTER NOW

- directly through the link: www.vincentonair.com

Please, contact the Organizing Secretariat for any further information:
registration@melanomabridge.org

SCIENTIFIC RATIONAL

Over the last few years, an extensive research has improved our understanding of tumor immunology and enabled the development of novel treatments that can harness the patient's immune system and prevent immune escape.

Through numerous clinical trials and real-world experience, a large amount of evidence of the potential for long-term survival with immunotherapy agents has been accumulated in various types of malignancy, starting from melanoma to extend to other tumors.

The results of these studies have also highlighted a number of recurring observations with immuno-oncology agents, including their potential for clinical application across a broad patient population and for both conventional and unconventional response patterns.

The clinical success of immune checkpoint blockade with anti-cytotoxic T-lymphocyte-associated antigen (CTLA)-4 and anti-programmed death (PD)-1/PD-ligand (L)1 inhibitor in melanoma and other cancers has encouraged increasing development of other immunotherapies, particularly monoclonal antibodies with other immune targets, adoptive cell transfer and vaccines. It has been estimated that there are over 3000 immuno-oncology trials ongoing, targeting hundreds of disease and immune pathways.

The successes of the immune-oncology is strongly correlated with the immune system ability of "memory" and adaptability, to improve the time of survival and without selecting resistant form of tumoral cells. Another advantage is that the efficacy of immunotherapy drugs does not seem to be particularly influenced by histology and mutations.

First session of the congress will be jointly organized with the Society for ImmunoTherapy of Cancer (SITC).

Hence, the state of the art of immunotherapy from the clinical point of view in various types of malignancies will be exhaustively discussed (lung, head and neck, ovarian, breast, kidney, gastrointestinal tract and lymphomas) and on targeting cancer through stimulation of innate immunity with intratumorals.

Then two "Great Debate" sessions, where counterpoint views from leading experts on specific controversial clinical issues will be presented and discussed from different points of view:

- Have B-cells a therapeutic role in the response to cancer immunotherapy? Yes or No
- Intralesional therapy: oncolytic virus vs other specific immune modulators
- Can vaccine transform cold into hot tumors? Yes or No
- Do early surrogates correlate with long-term overall survival? Yes or No
- Data science approaches to gain insights in to IO development: broad vs deep analytics.

Conclusions will be drawn after the last session on Neo-Adjuvant therapies in different types of cancer.

In order to disclose and stimulate the discussion of new approaches and strategies in the field of immunotherapy and based on the increasing success of "Immunotherapy Bridge" events over the years, a panel of international faculty will join the congress that will be held as webinar in December 2021.

Presidents of the Congress are Paolo A. Ascierto (National Cancer Institute, "Fondazione G. Pascale", Naples, Italy), Bernard A. Fox (Earle A. Chiles Research Institute at Providence Cancer Center, Portland, OR, US), Patrick Hwu (Moffitt Cancer Center, Tampa, FL, US) and Igor Puzanov (Roswell Park Comprehensive Cancer Center, Buffalo, NY, US), who will gather with the international faculty members in an interactive atmosphere which stimulates discussion and exchange of their experience regarding the most recent advances in research and clinical management of the immunotherapy of cancer.

SCIENTIFIC PROGRAM

Wednesday, Dec 1st, 2021



10:30 am	Introduction and objectives Paolo A. Ascierto
	SITC SESSION LESSONS LEARNED FROM CELL THERAPIES <i>Chairpersons:</i> Bernard A. Fox, Patrick Hwu
10:40 am	CAR-T Chrystal Paulos
10:55 am	Targeting solid malignancies with 'public' neoantigen-specific T cell receptors Christopher Klebanoff
11:10 am	Harnessing the power of a natural killer: bringing NK cells to immuno-oncology Tamara Laskowski
11:25 am	Understanding resistance to develop better CAR T immunotherapies Marco Ruella
11:40 am	Best of SITC 2021 for clinical development and trials Paolo A. Ascierto
11:55 am	Discussion
12:25 pm	LECTURE - Immunotherapy in Renal Cell Carcinoma: update and new perspectives <i>Chairperson:</i> Paolo A. Ascierto <i>Speaker:</i> Giuseppe Procopio
12:55 pm	Lunch**
01:45 pm	SYMPOSIUM - Combinations therapy across cancers <i>Chairperson:</i> Paolo A. Ascierto NSCLC, Cesare Gridelli - RCC, Camillo Porta - Melanoma, Paolo A. Ascierto
	SESSION 2 TRENDS IN IMMUNOTHERAPY <i>Chairpersons:</i> John B. Haanen, Sandro Pignata
02:35 pm	Integrating Head and Neck Cancer Immunotherapy into Locally Advanced Treatment Robert L. Ferris
02:50 pm	Pancreatic Cancer Elizabeth Jaffee
03:05 pm	Kidney Cancer Sergio Bracarda

SCIENTIFIC PROGRAM

Wednesday, Dec 1st, 2021



- 03:20 pm | GI cancer
Antonio Avallone
- 03:35 pm | Implications of the Tumor Microenvironment for Breast Cancer Immunotherapy
Leisha A. Emens
- 03:50 pm | Ovarian Cancer
Sandro Pignata
- 04:05 pm | *Coffee Break***
- 04:20 pm | PDI-blockade for Hodgkin Lymphoma: results, challenges and opportunities
Antonio Pinto
- 04:35 pm | Lecture: Merkel Cell Carcinoma
Paolo A. Ascierto
- 04:50 pm | Discussion
- GREAT DEBATE SESSION**
Chairpersons: Paolo A. Ascierto, Bernard A. Fox, Patrick Hwu, Igor Puzanov
- 05:20 pm | Have B-cells a therapeutic role in the response to cancer immunotherapy? Yes or No
Wolf Fridman, Tullia Bruno
- 05:50 pm | Discussion
- 06:00 pm | Intralesional therapy: oncolytic virus VS other specific immune modulators
Igor Puzanov, Omid Hamid
- 06:30 pm | Discussion
- 06:40 pm | Do early surrogates correlate with long-term overall survival? Yes or No
Michael A. Postow, Jeffrey Sosman
- 07:10 pm | Discussion

SCIENTIFIC PROGRAM

Thursday, Dec 2nd, 2021



SESSION 3 DRIVERS OF IMMUNE RESPONSES

Chairpersons: Alfredo Budillon, Bernard A. Fox

- 09:00 am Biotechnology tricks to harness CD137 (4-1BB) costimulation for cancer immunotherapy
Ignacio Melero Bermejo
- 09:15 am Super CD8-T cells, a new tool in immunotherapy; T cell reprogramming
Samir N. Khleif
- 09:30 am Immunotherapy for non-immunogenic tumors
Nina Bhardwaj
- 09:45 am Role of dendritic cells in immune response
Joshua Brody
- 10:00 am Pre-existing immune contexture for immunotherapy response
Jerome Galon
- 10:15 am T-cell regulome in immune checkpoint inhibition
Tomas Kirchhoff
- 10:30 am Discussion
- 10:45 am *Coffee Break***
- 10:55 am Predicting and mapping tumor regression following neoadjuvant immunotherapy
Janis M. Taube
- 11:10 am The virtual molecular tumor board as a tool for the delivery of precision oncology
Carlo Bifulco
- 11:25 am A new perspective on therapy-modulated tumor antigenicity
Sandra Demaria
- 11:40 am Cancer vaccine concepts for solving infectious diseases
Luigi Buonaguro
- 11:55 am PDL1 and IDO targeting vaccination for treatment of metastatic cancer
Inge Marie Svane
- 12:10 pm Update in the treatment of Non-Melanoma Skin Cancers, BCC and CSCC
- 12:25 pm **SYMPOSIUM** - Update in the treatment of Non-Melanoma Skin Cancers, BCC and CSCC
Chairperson: Paolo A. Ascierto
Paolo A. Ascierto, Dirk Schadendorf

SCIENTIFIC PROGRAM

Thursday, Dec 2nd, 2021



01:15 pm Lunch**

GREAT DEBATE SESSION

Chairpersons: Paolo A. Ascierto, Bernard Fox, Igor Puzanov

02:00 pm Can vaccine transform cold into hot tumors? Yes or No
Olivera J. Finn, Lisa H. Butterfield

02:30 pm Discussion

02:40 pm Data science approaches to gain insights in to IO development:
broad vs deep analytics
Theresa LaVallee, Andrew Futreal

03:10 pm Discussion

03:20 pm *Coffee Break***

SESSION

NEO ADJUVANT IMMUNOTHERAPY ACROSS CANCERS

Chairpersons: Paolo A. Ascierto, Elizabeth Burton

03:30 pm Overview and GU cancer
Padmanee Sharma

03:45 pm Breast Cancer
Elizabeth Mittendorf

04:00 pm Colon cancer
Myriam Chalabi

04:15 pm NSCLC
Tina Cascone

04:30 pm Melanoma
Rodabe Amaria

04:45 pm NMSC as Model for Neoadjuvant Immunotherapy
Neil Gross

05:00 pm Refining pathological response assessment in neoadjuvant therapy for melanoma
Richard Scolyer

05:15 pm Discussion

05:45 pm Conclusions
Paolo A. Ascierto, Bernard Fox, Igor Puzanov

2021

PRESIDENCY

**Paolo A. Ascierto**

Director, Medical Oncology, Melanoma, Cancer Immunotherapy and Development Therapeutics Department, National Cancer Institute "Fondazione G. Pascale", Naples, Italy

**Bernard A. Fox**

Chief of Molecular and Tumor Immunology Laboratory, Robert W. Franz Cancer Research Center - Earle A. Chiles Research Institute, Providence Cancer Institute, Portland, OR, US

**Patrick Hwu**

President & CEO, Moffitt Cancer Center, Tampa, FL, US

**Igor Puzanov**

Senior Vice President, Clinical Investigations Director, Center of Early Phase Clinical Trials, Chief, Melanoma Section, Roswell Park Comprehensive Cancer Center, Buffalo, NY, US

SCIENTIFIC BOARD

Sanjiv S. Agarwala

Professor & Chief, Haematology & Oncology, St Luke's University Hospital and Temple University, Bethlehem, PA, US

Paolo A. Ascierto

Director, Medical Oncology, Melanoma, Cancer Immunotherapy and Development Therapeutics Department, National Cancer Institute "Fondazione G. Pascale", Naples, Italy

Carlo Bifulco

Medical Director, PSJH System Genomics Laboratory, Providence St. Joseph Health, Director and Member, Translational Molecular Pathology, Earle A. Chiles Research Institute, Providence Cancer Institute, Portland, OR, US

Lisa H. Butterfield

Research Center Vice President, Parker Institute for Cancer Immunotherapy and Adjunct Professor of Microbiology and Immunology, University of California, San Francisco, CA, US

Elizabeth M. Burton

Executive Director, Strategic Translational Research Initiative Development, The University of Texas MD Anderson Cancer Center, Houston, TX, US

Corrado Caracò

Director of Melanoma and Skin Tumor Surgery, National Cancer Institute "Fondazione G. Pascale", Naples, Italy

Sandra Demaria

Professor of Pathology and Laboratory Medicine, Professor of Radiation Oncology and Adjunct Professor at Department of Pathology, Weill Cornell Medical College and NYU School of Medicine, New York, NY, US

SCIENTIFIC BOARD

Reinhard Dummer

Professor of Dermatology, University of Zurich Hospital, Department of Dermatology, Zurich, Switzerland

Bernard A. Fox

Chief of Molecular and Tumor Immunology Laboratory, Robert W. Franz Cancer Research Center - Earle A. Chiles Research Institute, Providence Cancer Institute, Portland, OR, US

Jerome Galon

Research Director, National Institute of Health and Medical Research (INSERM), Paris, France

Claus Garbe

Professor of Dermatology, President of the European Association of DermatoOncology (EADO), Center for Dermatooncology, Department of Dermatology, Eberhard Karls University, Tuebingen, Germany

Omid Hamid

Chief of Research/ Immuno-Oncology and Co-Director, Cutaneous Malignancy Program, The Angeles Clinic and Research Institute, Los Angeles, CA, US

Patrick Hwu

President & CEO, Moffitt Cancer Center, Tampa, FL, US

Giuseppe Masucci

Associate Professor, Department of Oncology-Pathology and KcRN, Karolinska Institutet, Cancer Centrum Karolinska (CCK), Karolinska University Hospital, Stockholm, Sweden

Iman Osman

Rudolf L. Baer MD Professor of Dermatology, Departments of Medicine (Oncology) and Urology, Director Interdisciplinary Melanoma Program, Associate Dean for Translational Research Support, New York University Langone, Medical School, New York, NY, US

Giuseppe Palmieri

President, Italian Melanoma Intergroup (IMI), Head of Unit of Cancer Genetics, Institute of Biomolecular Chemistry (ICB), National Research Council (CNR), Sassari, Italy

Michael A. Postow

Memorial Sloan Kettering Cancer Center, New York, NY, US

Igor Puzanov

Senior Vice President, Clinical Investigations Director, Center of Early Phase Clinical Trials, Chief, Melanoma Section, Roswell Park Comprehensive Cancer Center, Buffalo, NY, US

Magdalena Thurin

Program Director, Cancer Diagnosis Program, Division of Cancer Treatment and Diagnosis, NCI, NIH, Rockville, MD, US

Tara Withington

Executive Director Emeritus, Society of ImmunoTherapy for Cancer (SITC), Milwaukee, WI, US

FACULTY

Rodabe Amaria

Associate Professor, Department of Melanoma Medical Oncology, Division of Cancer Medicine, The University of Texas MD Anderson Cancer Center, Houston, TX, US

Paolo A. Ascierto

Director, Medical Oncology, Melanoma, Cancer Immunotherapy and Development Therapeutics Department, National Cancer Institute "Fondazione G. Pascale", Naples, Italy

FACULTY

Avallone Antonio

MD, SC of Abdominal Medical Oncology, National Cancer Institute "Fondazione G. Pascale", Naples, Italy

Nina Bhardwaj

Director of Immunotherapy, Waldman Chair in Cancer Research, Professor of Medicine, Hematology and Medical Oncology, The Tisch Cancer Institute, New York, NY, US

Carlo Bifulco

Medical Director, PSJH System Genomics Laboratory, Providence St. Joseph Health, Director and Member, Translational Molecular Pathology, Earle A. Chiles Research Institute, Providence Cancer Institute, Portland, OR, US

Sergio Bracarda

Director, Department of Oncology and Medical & Translational Oncology Unit, Azienda Ospedaliera Santa Maria, Terni, Italy

Joshua Brody

Director, Lymphoma Immunotherapy Program ICAHN, School of Medicine at The Mount Sinai Cancer Center, New York, NY, US

Tullia Bruno

Assistant Professor, UPMC Hillman Cancer Center, Pittsburgh, PA, US

Alfredo Budillon

Chief, Experimental Pharmacology Unit, Department of Translational Research, National Cancer Institute "Fondazione G. Pascale", Naples, Italy

Luigi Buonaguro

Director, Innovative Immunological Models Department of Research, National Cancer Institute "Fondazione G. Pascale", Naples, Italy

Elizabeth M. Burton

Executive Director, Strategic Translational Research Initiative Development, The University of Texas MD Anderson Cancer Center, Houston, TX, US

Lisa H. Butterfield

Research Center Vice President, Parker Institute for Cancer Immunotherapy and Adjunct Professor of Microbiology and Immunology, University of California, San Francisco, CA, US

Tina Cascone

Graduate School of Biomedical Sciences, Assistant Professor, Department of Thoracic/Head and Neck Medical Oncology, Division of Cancer Medicine, The University of Texas MD Anderson Cancer Center, Houston, TX, US

Myriam Chalabi

Medical Oncologist, Department of Gastrointestinal Oncology, The Netherlands Cancer Institute, Amsterdam, The Netherlands

Sandra Demaria

Professor of Pathology and Laboratory Medicine, Professor of Radiation Oncology, Weill Cornell Medical College, New York City, NY, US

Leisha A. Emens

Professor of Medicine, Director of Translational Immunotherapy for Women's Cancer Research Center, UPMC Hillman Cancer Center/Magee Women's Hospital, Co-Leader, Hillman Cancer Immunology/Immunotherapy Program, Pittsburgh, PA, US

Robert L. Ferris

Director, UPMC Hillman Cancer Center, Professor of Oncology, Associate Vice Chancellor for Cancer Research, Co-Director, Tumor Microenvironment Center Professor of Otolaryngology, of Immunology, and of Radiation Oncology, UPMC Hillman Cancer Center, Pittsburgh, PA, US

FACULTY

Olivera J. Finn

Distinguished Professor, Department of Immunology, University of Pittsburgh School of Medicine, Pittsburgh, PA, US

Bernard A. Fox

Chief of Molecular and Tumor Immunology Laboratory, Robert W. Franz Cancer Research Center - Earle A. Chiles Research Institute, Providence Cancer Institute, Portland, OR, US

Wolf H. Fridman

Director Cordeliers Research Centre, Paris, France

Andrew Futreal

Professor and Chair, Department of Genomic Medicine, The University of Texas Anderson Cancer Center, Houston, TX, US

Jerome Galon

Research Director, National Institute of Health and Medical Research (INSERM), Paris, France

Cesare Gridelli

Chief of Division of Medical Oncology, "San Giuseppe Moscati" Hospital, Avellino, Italy

Neil Gross

Director, Clinical Research, Department of Head and Neck Surgery, MD Anderson Cancer Center, Houston, TX, US

John B. Haanen

Consultant Medical Oncologist, CSO Immunotherapy and Staff Scientist in the Division of Immunology, Professor of Translational Immunotherapy of Cancer, Leiden University Medical Centre, Amsterdam, The Netherlands

Patrick Hwu

President & CEO, Moffitt Cancer Center, Tampa, FL, US

Elizabeth Jaffee

The Dana and Albert "Cubby" Broccoli, Professor of Oncology, Deputy Director, Sidney Kimmel Cancer Center at Johns Hopkins, Co-Director, Gastrointestinal Cancers Program, Baltimore, MD, US

Samir N. Khleif

Director of the Loop Immuno-Oncology Laboratory, Biomedical Scholar and Professor of Oncology, Georgetown University Medical School, Washington DC, US

Tomas Kirchhoff

Associate Professor, Perlmutter Cancer Center, New York, NY, US

Christopher Klebanoff

Head, Breast Immunotherapy Section, Memorial Sloan Kettering Cancer Center, New York, NY, US

Tamara Laskowski

Senior Director, Head of New Therapeutic Products - Personalized Medicine, Lonza Global

Theresa LaVallee

Vice President, Translational Medicine and Regulatory Affairs, Parker Institute for Cancer Immunotherapy, San Francisco, CA, US

Ignacio Melero Bermejo

Hepatology and Gene Therapy, Center for Applied Medical Research, University of Navarra, Spain

Elizabeth Mittendorf

Robert and Karen Hale Distinguished Chair in Surgical Oncology, Associate Chair for Research, Department of Surgery at Brigham and Women's Hospital, Director of Breast Immuno-Oncology program and Co-Director of Breast Cancer Clinical Research Program at Dana-Farber/Brigham and Women's Cancer Center, Boston, MA, US

Chrystal M. Paulos

Associate Professor, Director of Translational Research, Cutaneous Malignancies, Department of Surgery/Microbiology & Immunology, Winship Cancer Institute, Emory University, Atlanta, GA, US

FACULTY

Sandro Pignata

Director, Medical Oncology Division of Uro-Gynecology Department, National Cancer Institute "Fondazione G. Pascale", Naples, Italy

Antonio Pinto

Director of the Hematological Department, SC Director of Oncological Hematology, National Cancer Institute "Fondazione G. Pascale" Naples, Italy

Camillo Porta

Department of Biomedical Sciences and Human Oncology, University of Bari "A. Moro"; Chief, Division of Medical Oncology, Policlinico Consorziale, Bari, Italy

Michael A. Postow

Memorial Sloan Kettering Cancer Center, New York, NY, US

Giuseppe Procopio

Director Genitourinary Medical Oncology Unit, National Cancer Institute, Milan, Italy

Igor Puzanov

Senior Vice President, Clinical Investigations Director, Center of Early Phase Clinical Trials, Chief, Melanoma Section, Roswell Park Comprehensive Cancer Center, Buffalo, NY, US

Marco Ruella

Assistant Professor of Medicine, Hematology/Oncology Division and Center for Cellular Immunotherapies and Scientific Director of the Lymphoma Program, University Hospital of Pennsylvania, Philadelphia, PA, US

Dirk Schadendorf

Director & Chair, Department of Dermatology, Comprehensive Cancer Center at University Hospital, Essen, Germany

Richard Scolyer

Co-Medical Director, Melanoma Institute Australia; Senior Staff Specialist, Tissue Pathology and Diagnostic Oncology, Royal Prince Alfred Hospital; Professor Central Clinical School, University of Sydney, Sydney, Australia; Conjoint Professor, Central Clinical School, Sydney Medical School, Faculty of Medicine and Health, University of Sydney, Sydney, Australia

Padmanee Sharma

Professor, Departments of Genitourinary Medical Oncology and Immunology, Division of Cancer Medicine, the University of Texas MD Anderson Cancer Center, Houston, TX, US

Jeffrey A. Sosman

Professor, Medicine, Hematology Oncology Division, Feinberg School of Medicine, Northwestern University, Chicago, IL, US

Inge Marie Svane

Professor, Director, National Center for Cancer Immune Therapy, CCIT-DK, Department of Oncology, Copenhagen University Hospital, Herlev, Denmark

Janis M. Taube

Director, Division of Dermatopathology, Professor of Dermatology, Johns Hopkins University School of Medicine, Baltimore, MD, US



E.C.M.

Commissione Nazionale Formazione Continua



CONTINUING MEDICAL EDUCATION

3P Solution has been accredited by the Ministry of Health as a CME Standard Provider (code 327, authorized on October 15th, 2012).

3P Solution owns the responsibility for the content, quality and ethical correctness of this CME activity.

Immunotherapy Bridge congress has been accredited (ID CME 334885) with 22,5 CME credits with a formative technical-professional objective "Technical professional content (knowledge and competences) specifications of each profession, of all specialization and ultra-specialist activity. Rare disease", belonging to formative technical-professional objective area, for the following professions: medical doctors, pharmacists, biologists, nurses.

In order to receive credits, participants must:

1. Attend at least 90% of the accredited CME sessions (attendance check);
2. Complete the CME test by answering at least 75% of the questions correctly
3. Complete the evaluation form

MY ECM

Age.na.s activated MyEcm service (personalized page available to any health professional), which enables you to:

1. Consult the CME events offer;
2. Refer to the summary of events attended and earned credits;
3. Provide an assessment of courses organized by the Provider.

To access online services please log on to <http://ape.agenas.it/professionisti/myecm>.

If this meeting fulfilled your expectations, please click on  and give your assessment.

Immunotherapy Bridge is sponsored by an unrestricted grant from:

PLATINUM SPONSOR

SANOFI GENZYME  | **REGENERON**

GOLD SPONSOR

 **Bristol Myers Squibb™**

SILVER SPONSOR

 **BeiGene**

 **MSD**

SPONSOR

AstraZeneca 

 **Incyte**

 **Lunaphore**
Technologies

MERCK

 **Roche**

 **SUN**
PHARMA